Specialty Enzymes for Diagnostics

About ArcticZymes Technologies

ArcticZymes Technologies leverages its unique Arctic environment to discover and develop extremozymes—enzymes from extremophilic microorganisms—that function in non-standard conditions where conventional enzymes fail. With over 30 years of expertise, the company has pioneered industry breakthroughs like the first commercially available salt-active nuclease and COD UNG, targeting the high-growth markets of gene therapy, viral vector manufacturing, and molecular diagnostics. As a publicly traded company on the Oslo Stock Exchange, it focuses on providing GMP-grade enzymatic solutions to improve efficiency and reduce costs in biopharmaceutical production.

Therapeutic Areas